Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Accolade® TMZF® Hip Stem Outcomes Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stryker Orthopaedics
ClinicalTrials.gov Identifier:
NCT00957658
First received: August 10, 2009
Last updated: August 13, 2014
Last verified: August 2014

August 10, 2009
August 13, 2014
March 2006
May 2011   (final data collection date for primary outcome measure)
Combined Percentage (%) Cases Without Aseptic Loosening, Intraoperative Femoral Fracture or Thigh Pain [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
The combined success rates for aseptic loosening, intra-operative femoral fracture and thigh pain is no worse for patients with osteoporotic bone than for patients with non-osteoporotic bone [ Time Frame: 2 and 5 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00957658 on ClinicalTrials.gov Archive Site
  • Aseptic Femoral Stem Loosening [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Femoral Stem Fracture [ Time Frame: 2 and 5 years ] [ Designated as safety issue: Yes ]
  • Harris Hip Score, SF-12, KAS and PEQ [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Acetabular Insert Wear [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • DXA Scan Analysis [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Revision/removals, change in HHS, SF-12 & KAS at 2 & 5 yrs [ Time Frame: 2 and 5 years ] [ Designated as safety issue: Yes ]
  • Evaluate poly insert wear rates at 5 yrs [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Compare pre-op and post-op wrist DXA scans to assess progression of osteoporosis in both groups [ Time Frame: 2 and 5 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Accolade® TMZF® Hip Stem Outcomes Study
Accolade® TMZF® Study A Prospective, Post-market, Non-randomized, Multi-center Evaluation of the Accolade® TMZF® Hip Stem

The purpose of this study is to evaluate clinical and radiographic outcome data in patients implanted with the Accolade® TMZF® femoral stem.

A prospective, post-market, multi-centered clinical evaluation of the Accolade® TMZF® hip stem device. All patients enrolled will receive the study device. All study patients will undergo a preoperative central Dual energy X-ray absorptiometry (DXA) scan to determine bone mineral density (BMD) values.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Arthroplasty, Replacement, Hip
Device: Accolade® TMZF® Hip Stem
Accolade® TMZF® Hip Stem
Accolade® TMZF® Hip Stem
Accolade® TMZF® Hip Stem Study Device
Intervention: Device: Accolade® TMZF® Hip Stem
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
241
May 2014
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient is a candidate for a primary total hip replacement.
  2. Patient has primary diagnosis of osteoarthritis (OA).
  3. Male and non-pregnant female patients ages 18 to 90.
  4. Patient has signed an Institutional Review Board (IRB) approved, study specific Informed Patient Consent Form.
  5. Patient willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.
  6. Patient capable of undergoing a pre-op central DXA (dual-energy x-ray absorptiometry) scan for a bone mineral density (BMD) reading.

Exclusion Criteria:

  1. Patient has an active infection within the affected hip joint.
  2. Patient requires a revision surgery of a previously implanted total hip arthroplasty or hip fusion to the affected joint.
  3. Patient who is morbidly obese, Body Mass Index (BMI) > 40.
  4. Patient has a neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
  5. Patient has the following diagnosed systemic diseases: Paget's disease, renal osteodystrophy, lupus erythematosus, rheumatoid arthritis, metabolic bone disease and sickle cell anemia.
  6. Patient is immunologically suppressed or receiving chronic steroids more than 30 days. Patients receiving oral or IV steroids within one month of surgery.
  7. Patient is a prisoner.
Both
18 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00957658
59
No
Stryker Orthopaedics
Stryker Orthopaedics
Not Provided
Study Chair: Robert Krushell, MD Baystate Medical Center
Principal Investigator: Carlton Savory, MD Hughston Sports Medicine Center
Principal Investigator: Robert Zann, MD Boca Raton Community Hospital
Principal Investigator: Steven Gausewitz, MD Hoag Hospital
Principal Investigator: R. Scott Oliver, MD Jordan Hospital
Principal Investigator: Mary O'Connor, MD Mayo Clinic
Principal Investigator: Anthony Sanchez, MD Spartanburg Regional Health Service District, Inc
Principal Investigator: Mark Visk, MD Spartanburg Regional Health Service District, Inc
Principal Investigator: Steven Teeny, MD St. Clare Hospital
Principal Investigator: Alan Valadie, MD Coastal Orthopedics and Sports Medicine
Principal Investigator: Steven Zelicof, MD Sound Shore Medical Center of Westchester
Principal Investigator: James Bates, MD Alvarado Hospital
Stryker Orthopaedics
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP